210 related articles for article (PubMed ID: 12163391)
1. Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays.
Watson MA; Gutmann DH; Peterson K; Chicoine MR; Kleinschmidt-DeMasters BK; Brown HG; Perry A
Am J Pathol; 2002 Aug; 161(2):665-72. PubMed ID: 12163391
[TBL] [Abstract][Full Text] [Related]
2. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression.
Wrobel G; Roerig P; Kokocinski F; Neben K; Hahn M; Reifenberger G; Lichter P
Int J Cancer; 2005 Mar; 114(2):249-56. PubMed ID: 15540215
[TBL] [Abstract][Full Text] [Related]
3. Array expression meta-analysis of cancer stem cell genes identifies upregulation of PODXL especially in DCC low expression meningiomas.
Schulten HJ; Hussein D
PLoS One; 2019; 14(5):e0215452. PubMed ID: 31083655
[TBL] [Abstract][Full Text] [Related]
4. Comparison of gene expression profiles between frozen original meningiomas and primary cultures of the meningiomas by GeneChip.
Sasaki T; Hankins GR; Helm GA
Neurosurgery; 2003 Apr; 52(4):892-8; discussion 898-9. PubMed ID: 12657186
[TBL] [Abstract][Full Text] [Related]
5. Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype.
Fèvre-Montange M; Champier J; Durand A; Wierinckx A; Honnorat J; Guyotat J; Jouvet A
Int J Oncol; 2009 Dec; 35(6):1395-407. PubMed ID: 19885562
[TBL] [Abstract][Full Text] [Related]
6. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
[TBL] [Abstract][Full Text] [Related]
7. Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status.
Goutagny S; Yang HW; Zucman-Rossi J; Chan J; Dreyfuss JM; Park PJ; Black PM; Giovannini M; Carroll RS; Kalamarides M
Clin Cancer Res; 2010 Aug; 16(16):4155-64. PubMed ID: 20682713
[TBL] [Abstract][Full Text] [Related]
8. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.
Lusis EA; Watson MA; Chicoine MR; Lyman M; Roerig P; Reifenberger G; Gutmann DH; Perry A
Cancer Res; 2005 Aug; 65(16):7121-6. PubMed ID: 16103061
[TBL] [Abstract][Full Text] [Related]
9. Meningioma transcript profiles reveal deregulated Notch signaling pathway.
Cuevas IC; Slocum AL; Jun P; Costello JF; Bollen AW; Riggins GJ; McDermott MW; Lal A
Cancer Res; 2005 Jun; 65(12):5070-5. PubMed ID: 15958550
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of genes differentially expressed in meningiomas.
Murphy M; Pykett MJ; Harnish P; Zang KD; George DL
Cell Growth Differ; 1993 Sep; 4(9):715-22. PubMed ID: 7694637
[TBL] [Abstract][Full Text] [Related]
11. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.
Pérez-Magán E; Rodríguez de Lope A; Ribalta T; Ruano Y; Campos-Martín Y; Pérez-Bautista G; García JF; García-Claver A; Fiaño C; Hernández-Moneo JL; Mollejo M; Meléndez B
Neuro Oncol; 2010 Dec; 12(12):1278-90. PubMed ID: 20685720
[TBL] [Abstract][Full Text] [Related]
12. Expression and gene doses changes of the p53-regulator PPM1D in meningiomas: a role in meningioma progression?
Fukami S; Riemenschneider MJ; Kohno M; Steiger HJ
Brain Tumor Pathol; 2016 Jul; 33(3):191-9. PubMed ID: 26942600
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific.
Jun P; Hong C; Lal A; Wong JM; McDermott MW; Bollen AW; Plass C; Held WA; Smiraglia DJ; Costello JF
Neuro Oncol; 2009 Aug; 11(4):414-22. PubMed ID: 19001526
[TBL] [Abstract][Full Text] [Related]
14. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival.
Nakada S; Sasagawa Y; Tachibana O; Iizuka H; Kurose N; Shioya A; Guo X; Yamada S; Nojima T
Brain Tumor Pathol; 2019 Jan; 36(1):7-13. PubMed ID: 30519894
[TBL] [Abstract][Full Text] [Related]
15. Expression of IGF-II, IGFBP-2, -5, and -6 in meningiomas with different brain invasiveness.
Nordqvist AC; Mathiesen T
J Neurooncol; 2002 Mar; 57(1):19-26. PubMed ID: 12125963
[TBL] [Abstract][Full Text] [Related]
16. High thioredoxin reductase 1 expression in meningiomas undergoing malignant progression.
Esen H; Feyzioglu B; Erdi F; Keskin F; Kaya B; Demir LS
Brain Tumor Pathol; 2015 Jul; 32(3):195-201. PubMed ID: 25592259
[TBL] [Abstract][Full Text] [Related]
17. Microarray Expression Data Identify DCC as a Candidate Gene for Early Meningioma Progression.
Schulten HJ; Hussein D; Al-Adwani F; Karim S; Al-Maghrabi J; Al-Sharif M; Jamal A; Al-Ghamdi F; Baeesa SS; Bangash M; Chaudhary A; Al-Qahtani M
PLoS One; 2016; 11(4):e0153681. PubMed ID: 27096627
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation in the malignant transformation of meningiomas.
Gao F; Shi L; Russin J; Zeng L; Chang X; He S; Chen TC; Giannotta SL; Weisenberger DJ; Zada G; Mack WJ; Wang K
PLoS One; 2013; 8(1):e54114. PubMed ID: 23349797
[TBL] [Abstract][Full Text] [Related]
19. The molecular biology of hormone and growth factor receptors in meningiomas.
Black P; Carroll R; Zhang J
Acta Neurochir Suppl; 1996; 65():50-3. PubMed ID: 8738495
[TBL] [Abstract][Full Text] [Related]
20. Genetic alterations associated with progression and recurrence in meningiomas.
Pérez-Magán E; Campos-Martín Y; Mur P; Fiaño C; Ribalta T; García JF; Rey JA; Rodríguez de Lope A; Mollejo M; Meléndez B
J Neuropathol Exp Neurol; 2012 Oct; 71(10):882-93. PubMed ID: 22964784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
